Skip to main content

Market Overview

Abbott Launches Latest Insertable Cardiac Monitor For Irregular Heart Rhythms

Share:
Abbott Launches Latest Insertable Cardiac Monitor For Irregular Heart Rhythms
  • Abbott Laboratories (NYSE: ABTlaunched the Jot Dx, its latest insertable cardiac monitor (ICM), in the U.S.
  • The technology allows for remote detection and improved diagnostic accuracy of cardiac arrhythmias in patients.
  • Jot Dx offers clinicians and hospitals control of managing the flow of information through a feature that allows the viewing of abnormal heart rhythm data and provides the opportunity to simplify which irregular heart rhythms are recorded with a “key episodes” feature, according to a news release.
  • Data presented at Heart Rhythm 2021 demonstrated that Jot Dx provides a 63% data reduction burden.
  • Jot Dx ICM continuously monitors patient cardiac rhythms and connects directly to myMerlin, a downloadable mobile app that transmits real-time data to both the clinician and patient.
  • Price Action: ABT shares are down 0.12% at $121.24 during the market session on the last check Friday.
 

Related Articles (ABT)

View Comments and Join the Discussion!

Posted-In: BriefsNews Health Care General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com